![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NDUFS5 |
Gene summary for NDUFS5 |
![]() |
Gene information | Species | Human | Gene symbol | NDUFS5 | Gene ID | 4725 |
Gene name | NADH:ubiquinone oxidoreductase subunit S5 | |
Gene Alias | CI-15k | |
Cytomap | 1p34.3 | |
Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O43920 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4725 | NDUFS5 | CA_HPV_1 | Human | Cervix | CC | 1.23e-13 | -4.24e-01 | 0.0264 |
4725 | NDUFS5 | CA_HPV_3 | Human | Cervix | CC | 3.17e-04 | -1.15e-02 | 0.0414 |
4725 | NDUFS5 | CCI_1 | Human | Cervix | CC | 3.88e-25 | -1.19e+00 | 0.528 |
4725 | NDUFS5 | CCI_2 | Human | Cervix | CC | 2.81e-16 | -1.02e+00 | 0.5249 |
4725 | NDUFS5 | CCI_3 | Human | Cervix | CC | 5.68e-28 | -1.12e+00 | 0.516 |
4725 | NDUFS5 | CCII_1 | Human | Cervix | CC | 6.81e-42 | -1.18e+00 | 0.3249 |
4725 | NDUFS5 | sample3 | Human | Cervix | CC | 1.02e-14 | -2.87e-01 | 0.1387 |
4725 | NDUFS5 | H2 | Human | Cervix | HSIL_HPV | 4.56e-06 | -3.91e-01 | 0.0632 |
4725 | NDUFS5 | L1 | Human | Cervix | CC | 1.14e-11 | -4.65e-01 | 0.0802 |
4725 | NDUFS5 | T3 | Human | Cervix | CC | 7.10e-18 | -2.89e-01 | 0.1389 |
4725 | NDUFS5 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.66e-23 | 5.59e-01 | 0.0155 |
4725 | NDUFS5 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.45e-24 | 7.15e-01 | -0.1808 |
4725 | NDUFS5 | HTA11_1938_2000001011 | Human | Colorectum | AD | 7.82e-36 | 1.21e+00 | -0.0811 |
4725 | NDUFS5 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.26e-03 | 2.89e-01 | -0.1088 |
4725 | NDUFS5 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.69e-38 | 9.00e-01 | -0.1954 |
4725 | NDUFS5 | HTA11_411_2000001011 | Human | Colorectum | SER | 1.94e-09 | 1.01e+00 | -0.2602 |
4725 | NDUFS5 | HTA11_2112_2000001011 | Human | Colorectum | SER | 7.11e-09 | 1.16e+00 | -0.2196 |
4725 | NDUFS5 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.98e-21 | 9.35e-01 | -0.1207 |
4725 | NDUFS5 | HTA11_83_2000001011 | Human | Colorectum | SER | 2.49e-25 | 1.09e+00 | -0.1526 |
4725 | NDUFS5 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.30e-46 | 1.12e+00 | -0.1464 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000906033 | Thyroid | ATC | aerobic respiration | 126/6293 | 189/18723 | 1.21e-20 | 2.02e-18 | 126 |
GO:004603434 | Thyroid | ATC | ATP metabolic process | 167/6293 | 277/18723 | 5.60e-20 | 8.64e-18 | 167 |
GO:000609134 | Thyroid | ATC | generation of precursor metabolites and energy | 256/6293 | 490/18723 | 6.55e-18 | 7.69e-16 | 256 |
GO:004533333 | Thyroid | ATC | cellular respiration | 140/6293 | 230/18723 | 1.76e-17 | 1.89e-15 | 140 |
GO:000611933 | Thyroid | ATC | oxidative phosphorylation | 96/6293 | 141/18723 | 5.40e-17 | 4.88e-15 | 96 |
GO:001598034 | Thyroid | ATC | energy derivation by oxidation of organic compounds | 177/6293 | 318/18723 | 3.60e-16 | 2.92e-14 | 177 |
GO:004277333 | Thyroid | ATC | ATP synthesis coupled electron transport | 69/6293 | 95/18723 | 7.86e-15 | 4.78e-13 | 69 |
GO:004277533 | Thyroid | ATC | mitochondrial ATP synthesis coupled electron transport | 69/6293 | 95/18723 | 7.86e-15 | 4.78e-13 | 69 |
GO:002290034 | Thyroid | ATC | electron transport chain | 106/6293 | 175/18723 | 2.20e-13 | 1.06e-11 | 106 |
GO:002290433 | Thyroid | ATC | respiratory electron transport chain | 76/6293 | 114/18723 | 5.17e-13 | 2.30e-11 | 76 |
GO:001964633 | Thyroid | ATC | aerobic electron transport chain | 62/6293 | 87/18723 | 7.42e-13 | 3.23e-11 | 62 |
GO:003310832 | Thyroid | ATC | mitochondrial respiratory chain complex assembly | 65/6293 | 93/18723 | 8.86e-13 | 3.81e-11 | 65 |
GO:000612032 | Thyroid | ATC | mitochondrial electron transport, NADH to ubiquinone | 40/6293 | 51/18723 | 6.54e-11 | 2.10e-09 | 40 |
GO:001025732 | Thyroid | ATC | NADH dehydrogenase complex assembly | 43/6293 | 57/18723 | 1.20e-10 | 3.75e-09 | 43 |
GO:003298132 | Thyroid | ATC | mitochondrial respiratory chain complex I assembly | 43/6293 | 57/18723 | 1.20e-10 | 3.75e-09 | 43 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0019018 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
hsa0501418 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
hsa0472318 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
hsa0019019 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
hsa0502019 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
hsa05415110 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
hsa0501019 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
hsa0501619 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NDUFS5 | SNV | Missense_Mutation | rs368988409 | c.206G>A | p.Arg69Gln | p.R69Q | O43920 | protein_coding | tolerated(0.06) | benign(0.116) | TCGA-AC-A7VB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NDUFS5 | SNV | Missense_Mutation | novel | c.163N>A | p.Glu55Lys | p.E55K | O43920 | protein_coding | deleterious(0) | possibly_damaging(0.896) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
NDUFS5 | SNV | Missense_Mutation | novel | c.137N>A | p.Gly46Glu | p.G46E | O43920 | protein_coding | tolerated(0.06) | probably_damaging(1) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
NDUFS5 | SNV | Missense_Mutation | c.94N>G | p.Arg32Gly | p.R32G | O43920 | protein_coding | deleterious(0.03) | possibly_damaging(0.591) | TCGA-E2-A1LG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
NDUFS5 | SNV | Missense_Mutation | c.189N>A | p.Phe63Leu | p.F63L | O43920 | protein_coding | tolerated(0.16) | benign(0.04) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
NDUFS5 | SNV | Missense_Mutation | c.184G>T | p.Asp62Tyr | p.D62Y | O43920 | protein_coding | deleterious(0.05) | benign(0.046) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NDUFS5 | SNV | Missense_Mutation | c.223C>T | p.Arg75Cys | p.R75C | O43920 | protein_coding | tolerated(0.07) | benign(0.015) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
NDUFS5 | SNV | Missense_Mutation | rs375631916 | c.205N>T | p.Arg69Trp | p.R69W | O43920 | protein_coding | tolerated(0.11) | benign(0.027) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
NDUFS5 | SNV | Missense_Mutation | rs541997196 | c.190N>A | p.Val64Ile | p.V64I | O43920 | protein_coding | tolerated(0.8) | benign(0) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NDUFS5 | SNV | Missense_Mutation | c.99N>G | p.Cys33Trp | p.C33W | O43920 | protein_coding | deleterious(0) | benign(0.054) | TCGA-95-7567-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4725 | NDUFS5 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 | |
4725 | NDUFS5 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
4725 | NDUFS5 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE |
Page: 1 |